AU775043B2 - Mutant Tn5 transposase enzymes and method for their use - Google Patents

Description

MUTANT TN5 TRANSPOSASE ENZYMES AND METHOD FOR THEIR USE CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of US provisional patent application number 60/146,686, filed on August 2,1999, which is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION Bacterial transposons such asTn5 evolved within the cell by maintaining a low mobility level. While necessary for the transposon to survive, the low mobility level has inhibited the ability of researchers to detail the molecular transposition process and to exploit the transposition process for use, e. in the development of new diagnostic and therapeutic resources. Tn5 is a conservative "cut and paste" transposon of the IS4 family (Rezsohazy, Hallet, Delcour, J., and Mahillon, J, "The IS4 family of insertion sequences: evidence for a conserved transposase motif," Mol Microbiol. 9: 1283-1295 (1993)) that encodes a 53kD transposase protein (Tnp) that is responsible for its movement. The wild-type Tn5 transposase amino acid and nucleic acid sequences are known. Ahmed, A. and Podemski, L. The Revised Sequence ofTn5. Gene 154(1), 129-130 (1995), incorporated by reference as if set forth herein in its entirety. A nucleic acid sequence that encodes wild-type Tn5 transposase is attached as SEQ IDNO: 1. A polypeptide sequence encoded by SEQ IDNO: 1 which corresponds to wild-type Tn5 transposase is attached as SEQ IDNO: 2. The Tnp protein facilitates movement of the entire element by binding initially to each of two 19bp specific binding sequences termed outside end (OE; SEQ ID NO: followed by formation of a nucleoprotein structure termed a synapse, blunt ended cleavage of each end, association with a target DNA, and then strand transfer (Reznikoff, W. Bhasin, Davies, D.

Goryshin, I. Mahnke, L. A.,Naumann, Rayment,I., Steiniger-White, and Twining, "Tn5: A molecular window on °oe°* o* [I\DAYLIB\LIBFF]06494.doc:NSS WO 01/09363 PCT/US00/21052 transposition," Biochem. Biophys. Res. Commun. 266:729-34 (1999)). transposase can also promote movement of a single insertion sequence by using a combination of OE and inside end (IE; SEQ ID NO:4) sequences. The IE is also 19bp long and is identical to OE at 12 of 19 positions (Fig. In vivo, Tn5 transposase exhibits a marked preference for OE in E. coli. Transposase recognition and binding to IE is inhibited in E. coli by the presence of two dam methylation sites (GATC palindromes) which add four methyl groups per inside end sequence (IE" also depicted as SEQ ID NO:4, methylation not shown) (YinJ.C.P., Krebs,M.P., and Reznikoff,W.S., "Effect of dam Methylation on Tn5 Transposition," J. Mol Biol, 199:35-45 (1988), incorporated by reference as if set forth herein in its entirety). This methylation reduces transposition by reducing protein-DNA primary recognition (Jilk, York,D., and Reznikoff, "The organization of the outside end of transposon Tn5," J. Bacteriol.

178:1671-1679 (1996)).

A principal roadblock to understanding how Tn5 transposes is the fact that purified wild-type Tnp has no detectable activity in vitro. Recently, a double mutant hyperactive form of transposase ("Tnp EK/LP") that promotes all steps of the transposition reaction in vitro was developed. The Tnp EKILP protein differs from wild-type Tn5 Tnp at position 54 (Glu to Lys mutation) and at position 372 (Leu to Pro mutation), in addition to a non-essential but advantageous change at position 56 that prevents production of a so-called inhibitor protein. The modified hyperactive Tnp protein retains the dramatic preference for OE (or OE-like) termini of wild-type transposase. Tnp EK/LP has clarified many aspects of Tn5 transposition that were not previously adequately addressable in vivo.

In vitro polynucleotide transposition is a powerful tool for introducing random or targeted mutations into a genome. Useful in vitro transposition systems based upon the transposon are disclosed in US Patent No. 5,925,545 and International Publication No. WO 00/17343, both of which are incorporated herein by reference in their entirety as if set forth herein.

A Tnp protein having an ability to discriminate between IE and OE and having a preference for binding IE is desired to permit directed nucleic acid transposition and to facilitate more complex transposition and genetic engineering strategies of the type disclosed in the above-mentioned patent and application than are available using a Tnp having a single specificity for OE. A Tnp having an enhanced preference for IE n is also desired because methylation of DNA in common dam+ bacterial hosts inhibits binding of existing Tn5 transposases and reduces the ability of existing transposases to facilitate movement of IE-defined transposons.

BRIEF SUMMARY OF THE INVENTION According to a first embodiment of the invention, there is provided an isolated mutant transposase protein modified relative to wild-type Tn5 transposase protein, the mutant transposase differing from the wild-type protein at a position selected from the group consisting of amino acid 58 and amino acid 372, wherein the mutant Tn5 transposase protein has a preference for Tn5 inside ends over Tn5 outside ends.

According to a second embodiment of the invention, there is a polynucleotide that encodes a transposase as defined in accordance with the first embodiment of the invention.

According to a third embodiment of the invention, there is provided a system for transposing a transposable DNA sequence in vitro, the system comprising: the mutant Tn5 transposase modified relative to a wild-type Tn5 transposase, as defined in accordance with the first embodiment of the invention; a donor DNA molecule comprising the transposable DNA sequence, the sequence being flanked at its and 3' ends by a wild-type IE sequence; and a target DNA molecule into which the transposable element can transpose.

According to a fourth embodiment of the invention, there is provided a method for in vitro transposition, the method comprising the steps of: combining a donor DNA molecule that comprises a transposable DNA sequence of interest, the DNA sequence of interest being flanked at its and ends by a wild-type Tn5 inside end sequence, with a target DNA molecule and a mutant Tn5 transposase as defined in accordance with the first embodiment of the invention in a suitable reaction buffer for a period of time sufficient for the enzyme to catalyse in vitro transposition. The present invention is summarized in that a transposase protein modified relative to wild-type Tn5 Tnp as disclosed herein preferentially promotes transposition of a target sequence flanked with wild-type Tn5 transposon inside ends (IE) rather than outside ends (OE) without regard to whether the IE sequences are methylated.

In a related aspect, the present invention is also summarized in that a transposase modified relative to wild-type Tn5 Tnp as disclosed herein has a preference for IE over OE and is hyper- active with regard to transposition frequency.

[I:\DAYLIB\LIBFF]06494.doc NSS In another related aspect, the present invention is also summarized in that a transposase modified relative to wild-type Tn5 Tnp as disclosed herein has a preference for IE over OE and catalyzes transposition at a high level even when the IE sequences are methylated. In contrast, wild-type Tn5 transposase does not efficiently recognize methylated IE sequences.

In yet another related aspect, the present invention is summarized in that a transposase according to the invention includes a mutation relative to wild typeTn5 transposase that either (1) alters binding of the transposase to the DNA termini or enhances transposition or both.

The mutation can be end-sequence-specific (as in the exemplified embodiments that alter DNA binding) or non-specific (as in the exemplified embodiment that enhances transposition.

In still another related aspect, the present invention is summarized in that a transposase according to the invention has a greater preference for IE than OE and differs from wildtype Tnp in at least one an amino acid selected from the group consisting of amino acid 58, amino acid 344 and amino acid 372.

In still another related aspect, the present invention is summarized in that a transposase according to the invention differs from wild-type Tnp in that it contains at least one of a mutation from glutamic acid to valine at amino acid 58, a mutation from glutamic acid to lysine at amino acid 344, and a mutation from leucine to glutamic acid at amino acid 372.

In another related aspect the invention is summarized in that the transposase of the invention can also exhibit a greater preference for IE by reducing the preference for OE. A mutation at amino acid position 8 relative to wild-type transposase can reduce the preference of a transposase for OE, and thereby increase the apparent preference for IE. A mutation from arginine to cysteine can accomplish this modification. A transposase protein of the invention can promote more transposition of an IE flanked target sequence in vivo or in vitro than wild-type Tn5 transposase does. A suitable method for determining transposase enzyme activity in vitro is disclosed herein and in US Patent No. i 5,925,545, incorporated herein by reference in its entirety. A oooo [I \DAYLIB\LIBFF06494 doc:NSS WO 01/09363 PCT/US00O/2102 suitable method for determining transposase activity in vivo is disclosed herein.

The modified Tn5 Tnp of the present invention differs from wild-type Tn5 Tnp by virtue of at least one a change to an amino acid position, where the change is selected from the group consisting of(l) a change at amino acid position 58 that reduces or eliminates a negative interaction between the Tnp and a methylated DNA residue and a change at amino acid position 344 that alters DNA binding. In addition to the changes noted herein, the modified Tnp's of the invention can also include a change at position 56 (such as a Met to Ala change) that prevents production of the so-called inhibitor protein that interferes with transposition. Moreover, the mutant transposase proteins can contain mutations in addition to those noted above. Additional mutations relative to the wild-type Tn5 Tnp are disclosed below. The effect of each mutation is disclosed below and it is understood that the applicants have identified amino acid residues of the protein that have a direct impact upon function and that other modifications at the same positions can have effects comparable to, greater than or lesser than those noted on the preference of the protein for inside ends. The wild-type transposase amino acid sequence is presented in the Sequence Listing. Exemplified changes relative to that wild-type transposase are presented in the text of this application.

The invention is further summarized in that the enzymes disclosed herein facilitate a simple, in vitro system and method for introducing any transposable element from a donor DNA into a target DNA when the transposable element DNA is flanked on either side by IE termini inverted relative to one another. Few other requirements on either the donor DNA or the target DNA are envisioned. It is thought that Tn5 has few, if any, preferences for insertion sites, so it is possible to use the system to introduce desired sequences at random into target DNA. Therefore, it is believed that this system and method, employing the modified transposase described herein and a simple donor DNA, is broadly applicable to introduce changes into any target DNA, without regard to its nucleotide sequence. It will, thus, be applied to many problems of interest to those skilled in the art of molecular biology.

Finally, although the changes noted herein are disclosed in terms of changes at the protein level, it is well within the ability of a skilled artisan to modify a polynucleotide that encodes a Tn5 transposase protein to encode the modified proteins of the invention. The skilled artisan also understands the degeneracy of the genetic code and understands that a plurality of codons can direct the production of a single amino acid residue.

The invention will be more fully understood upon consideration of the following detailed description taken in conjunction with the accompanying drawings.

WO 01/09363 PCT/USOO/21052 BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS Fig. 1 depicts the structure of Tn5 transposase and the nucleotide sequences of outside ends inside ends methylated inside ends (IEm), and modified IE (IE12A).

Fig. 2 is a schematic depiction of the molecular basis for a papillation assay for observing transposition in vivo.

Fig. 3A depicts the locations of mutations observed in four successive rounds B, C, D) of mutagenesis/recombination. Fig. 3B depicts the in vivo transposition profile of each of the mutants of Fig. 3A.

Fig. 4 depicts the relative preference of mutant transposases obtained in successive rounds of mutagenesis/recombination for OE and IE in a dam- strain of E.

coli.

Fig. 5A depicts a plasmid suitable for use in an in vitro transposition method.

Fig. 5B depicts the transposition products obtained using a mutant transposase of the invention to catalyze transposition in vitro. Fig. 5C further characterizes the products of lane 2 of Fig. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Random mutagenesis studies performed on the Tnp gene have demonstrated that it is possible to isolate mutations in the protein that increase the rate of transposition (Krebs and Reznikoff, 1988; DeLong, and Syvanen, "Trans-acting transposase mutant from Tn5," P.N.A.S. U.S.A. 88:6072-6 (1991); Wiegand, and Reznikoff, "Characterization of two hypertransposing Tn5 mutants," J. Bacteriol.

174:1229-1239 (1992); Weinrcich, Gasch, Reznikoff, "Evidence that the cis preference of the Tn5 transposase is caused by nonproductive multimerization," Genes. Dev. 8: 2363-2374 (1994); Zhou, Rezaikoff, "Tn5 mutants that alter DNA binding specificity," J. Mol. Biol. 271:362-73. (1997), incorporated by reference as if set forth herein in its entirety). This makes transposase unique in comparison to most enzymatic proteins that appear to have evolved for maximum in vivo activity.

This is likely due to the fact that high rates of transposition would be detrimental to the survival of the transposon and hence transposase has evolved to have an 'optimal' level that is much lower than its maximum attainable level.

Applicants have isolated a set of related mutant transposase proteins that differ from wild type Tn5 transposase in that the mutant proteins show a preference in a transposition system for inside ends and in some cases, methylated inside ends (IEm), rather than for outside ends which are unmethylated because they lack a methylation site. The end preference of a mutant transposase can characterized either WO 01/09363 PCT/US00/21052 by the in vivo transposition frequency observed when it is used in a system in which the target polynucleotide is flanked with either OE and IE* termini, or by the ratio of the in vivo transposition frequencies observed when it is used in a pair of systems in which the target polynucleotide is flanked with OE and IEM termini, respectively.

Although applicants have exemplied a number of transposase proteins differing from wild-type TnS Tnp at one, four, five, and seven mutations, one can reasonably predict from their analysis the effects of particular individual mutations.

EXAMPLE

Overview A number of related methods were used to obtain the family of mutants disclosed herein. In a first method, the applicants obtained mutants that restored in vivo transposition activity to a mutated end binding sequence that is not recognized as a substrate by wild type transposase. In a second method, the applicants introduced directed mutations into certain products of the first method to determine the preferred structure of a mutant transposase according to the invention.

In the first method, the mutant IE end binding sequence contains an adenine in place of thymine at position 12 ("IE12A"; SEQ ID NO:5). The thymine-to-adenine change in IE12A destroys one of the two methylation sites of wild-type IE. Applicants used sPCR, a combinatorial, random directed mutagenesis technique to obtain modified transposase proteins that can restore transposition activity to polynucleotides flanked with IE12A. sPCR was developed and described Stemmer, "Rapid evolution of a protein in vitro by DNA shuffling," Nature 370:389-391 (1994) and Stemmer, W.P., "DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution," Proc. Natl. Acad. Sci. U.S.A. 91:10747-10751 (1994), both of which are incorporated by reference herein as if set forth in their entirety. Briefly, DNA is manipulated in vitro in the sPCR method to introduce point mutations and to allow random recombination within a population of mutant sequences. The mutated genes can be cloned into plasmids which can be selected for increased activity in vivo. Clones having desirable phenotypes are then used as substrates for subsequent rounds of mutagenesis/recombination and selection for a further improved phenotype.

The sPCR method can be used in conjunction with a screen (instead of a selection) in which a modest number of colonies are analyzed per round (Crameri, Whitehorn, and Stemmer, "Improved green fluorescent protein by molecular evolution using DNA shuffling," Nat. Biotechnol. 14:315-319 (1996), and Zhang, Dawes, and Stemmer, "Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening," Proc. Natl. Acad. Sci. U.S.A. 94,

II

WO 01/09363 PCT/US00/21052 4504-4509 (1997), both of which are incorporated by reference herein as if set forth in their entirety. A papillation assay described in the Example that follows was used as a screen for transposase mutants that restore transposition activity to polynucleotides flanked with IE12A. The papillation assay is a modification of the assay described by Krebs, and Reznikoff, "Use of a Tn5 derivative that creates lacZ translational fusions to obtain a transposition mutant," Gene 63:277-85 (1988), incorporated by reference in its entirety as if set forth herein. In the papillation assay, productive transposition in frame into an actively expressed gene results in formation of a P-Gal fusion protein. These cells turn blue (due to presence of X-gal) and grow at an increased rate within the colony (lactose utilization). The rate at which these papillae form can be used to compare transposition rates promoted by mutated proteins.

The applicants determined the ability of mutant transposases identified using the first method to catalyze in vivo transposition of polynucleotides flanked either with wildtype OE or with wild-type IE in a dam- strain the nucleic acid was unmethylated).

Among the mutants identified using the method, applicants identified a mutant transposase ("Tnp sC7") that retained near-wild-type activity with OE-flanked polynucleotides but which had very high activity with IE-flanked polynucleotides and even higher activity with IE-flanked polynucleotides when tested in a dam+ strain the nucleic acid was methylated, subsequently Tnp sC7 contains seven mutations relative to wild-type transposase.

In the second method, it was subsequently determined that a related mutant transposase ("Tnp sC7v2.0") having only four of the seven mutations of Tnp sC7 exhibited a still higher IEE:OE activity ratio. Both Tnp sC7 and Tnp sC7v2.0 contain a mutation that inhibits OE related activity (R8C), two mutations that specifically increase IEM related activity (E58V, E344K), and a mutation that increases transposition of polynucleotides flanked by either IEM or OE (L372Q).

Obtaining the mutant Tnp's The modified papillation assay used to screen for productive transposition is shown and described in Fig. 2. In a first plasmid ("pRZ9904 (IE12A/IE12A)") used, a pair of inverted IE12A termini flank a polynucleotide that contains a lacZ gene but which lacks both a promoter and a translational start site. A second plasmid ("pRZ9905") used in the assay, encodes for transposase that can move the lacZcontaining polynucleotide. Plasmids having these attributes can readily be constructed by a skilled artisan. Materials and methods are detailed below.

Five random mutants that suppressed the end sequence mutation and yielded papillae after an initial cycle of mutagenesis/recombination. Equal amounts of plasmid WO 01/09363 PCT/US00/21052 encoding each of these mutant transposases were then used as the initial substrates for a second round of mutagenesis/recombination. Following this second round, the mutated transposase genes were cloned into vector DNA and screened a second time for transposition activity with IE12A-defined polynucleotides via the papillation screen.

From this second round, a total of 6 active mutants were isolated. A third round of mutagenesis/recombination was then performed followed by screening for activity with the mutant end sequence. This time hundreds of colonies were positive for papillation.

Of these, 7 were clearly more active than the others and were isolated to serve as a template for a fourth round. In the fourth round of screening there were hundreds of transposing colonies visualized during the screening process. None of these, however, were as active as the most active mutant from the third round of mutagenesis/recombination (Tnp sC6).

The most active isolate from each round was sequenced and tested for transposition activity with IE12A defined transposons in a quantitative papillation assay (see Figs. 3A and 3B). Fig. 3A depicts the mutations relative to wild-type Tnp of Tnp (best first round papillator), sB2 (best second round papillator), sC6 (best third round papillator), and sD5 (best fourth round papillator). Fig. 3B depicts the transposition activities of the four isolates in vivo in the papillation assay. Tnp WT was also tested but failed to promote a single detectable transposition event. The mutation Q81H is the only mutation that distinguishes the most active mutant, sC6, isolated in the third round, from the noticeably less active mutant sB2, isolated in the second round. A second isolate from the third round, Tnp sC7, is similar to the fourth round isolate except that it has two additional mutations (D217A and E344K). Tnp sC7's activity with IEl2A defined transposons is similar to that of the fourth round isolate sD5 (data not shown).

The mutant Tnp's can promote transposition of OE- and IE-defined transposons The mutant Tnp's described above were of initial interest because they could restore transposition activity to transposons flanked with IE12A termini that are inactive in the presence of wild-type Tnp. Although the transposase mutants functioned increasingly well with these transposons, the transposition rate did not approach the level of activity that is required in vitro. In fact, the in vivo activity of Tnp sC6 with IE12A ends only restored activity to a level similar to that of Tnp WT with transposons defined by OE (data not shown).

Interestingly, however, most of the isolated mutants were hyperactive with transposons defined by at least one of the native end sequences (IE or OE). These transposition preferences were determined in a dam- (DNA unmethylated) strain using WO 01/09363 PCT/US00/21052 the mating out assay of Goryshin,I.Y., Kil, and Reznikoff, "DNA length, and twisting constraints on IS50 transposition," Proc Natl Acad Sci U S A 91:10834-10838 (1994), incorporated by reference as if set forth herein in its entirety.

Fig. 4 depicts the in vivo transposition activity of 25 mutant Tnps with IE and OE defined transposons in the mating-out assay in a dam- strain, normalized to the activity of wild-type Tnp (6.5X10 5 normalized to In this assay in a dam- environment, Tnp WT shows generally equivalent activity levels whether the substrate polynucleotide is flanked with IE or with OE. On the other hand, many of the mutants exhibited higher activity with IE than with OE. This is not surprising, since the mutants were obtained in a screen using IE12A, which differs from IE at only 1 nucleotide. In contrast, OE differs from IE12A at 6 nucleotides. One mutant in particular, Tnp sC7, displayed a very interesting phenotype. It is markedly hyperactive with IE transposons while exhibiting little change in the frequency of OE transposon movement. The ability to discriminate between IE and OE is important because it facilitates multi-part transpositions that separately employ IE and OE ends, where a reaction can be directed one way or another by providing a transposase that prefers either IE or OE. A preference for IE over OE of greater than about 5-fold may be suitable, though a preference of greater than about fold for IE is more preferred. A preference of greater than about 20-fold is still more preferred. Fig. 4 demonstrates that a skilled artisan can obtain such mutant transposases using the methods disclosed herein. In particular, mutants sBl, sC6, sC7, sDl and sD3 are examples of such mutants.

Even more significantly, however, Tnp sC7 is not only not inhibited for transposition activity by methylated IE (which reduces Tnp WT levels by -102) but actually prefers IEM transposons to those flanked by IE, as is shown in the mating out results of Table I which indicate that transposition frequency with OE is reduced in a dam+ strain for both Tnp sC7 and Tnp WT. Since binding of Tnp to OE is not affected by dam methylation, this difference merely reflects the difference in transposition activity between dam+ strains and dam- strains. Despite this reduction, the rate of IE defined transposition facilitated by Tnp sC7 is even higher in the dam+ strain due to the presence of methylation in the ends. In contrast, methylation of the end sequence inhibits recognition by wild-type transposase. On the basis of its ability to discriminate between IE and OE, and because of its insensitivity to methylation of IE, subsequent attention was directed to Tnp sC7.

WO 01/09363 PCT/US00/21052 Table 1. In vivo transposition rate ofTnp WT and Tnp sC7.

JCMlOl (dam-) RZ212 (dam+) IE freq. OE freq. IE/OE IE m freq. OE freq. IEE/OE TnpWT 6.5X10 6.5X10 5 1.0 1.0X10 4 3.1XI0 6 3.2X10- 3 TnpsC7 1.8X10- 3 3.7X10- 5 50 2.6X10'- 3.3X10 6 794 The role of the individual Tnp sC7 mutations in transposition activity To understand how individual mutations affect the activity of the protein and in an effort to maximize the activity of the protein and its ability to discriminate between

IE

m and OE, the applicants strategically prepared more variant transposases using information obtained from sC7, which as noted above, contained seven mutations relative to wild type transposase. Since a comprehensive trial of all possible combinations of these seven mutations was cumbersome (128 possible combinations) two classes of seven mutants each were engineered. In each mutant of the first class, a unique mutation from sC7 was engineered to revert to wild-type at that position. This set of so-called "minus one" mutant transposases included all possible mutants having 6 of the 7 mutations. In each mutant of the second class, wild-type transposase was engineered to contain exactly one of the 7 mutations from sC7. The set of so-called "plus one" mutant transposases included all possible mutants having only 1 of the 7 mutations. These mutant proteins were all assayed for in vivo transposition activity with

IE

M

and OE by mating out assays. The results of the analysis are shown in Table 2.

WO 01/09363 PCTIUS00/21052 Table 2. Results of 'minus ones/plus ones' analysis.

'minus one' IEm 'minus one' OE 'plus one' IE m 'plus one' OE freq. norm. freq. norm. freq. norm. freq. norm.

Wild-type 1.0X10- 1.0 3.1X10 6 sC7 2.6X10 3 1.0 3.3X10 5 RC8C 3.1X10- 3 1.2 6.0X10- 1.8 4.0X10- 7 0.1 E58V 1.8X10 6 6.9X104 1.1X10- 0.3 4.0X104 4X10 4 1.4X10- A157T 3.1X10 3 1.2 4X10- 6 1.2 6.6X10- 7 0.2 T171S 2.8X10 3 1.1 2.6X10- 0.8 5.6X10- 9 0.6 1.8X10 0.6 D217A 3.7X10- 3 1.3 4.5X10 1.4 3.4X10 6 1.1 E344K 5.5X10 4 0.2 1.7X10- 5.2 4.3X10- 8 4.3 6.8X10- 7 0.2 L372Q 2.6X10 4 0.1 2.8X10- 7 0.1 8.9X10 8 8.9 1.1X10 5 a. 'Minus ones' contain all mutations present in Tnp sC7 except at indicated position. e.g. R8C 'minus one' contains the wild-type argenine at position 8.

b. 'Plus ones' are Tnp WT except that the indicated amino acid is mutated to the residue present in Tnp sC7. E.g. R8C 'plus one' contains a cysteine at amino acid 8.

Sequence-specific mutations. The mutation E58V has the most profound effect of all the mutations on the activity of Tnp sC7. This mutation in the wild-type background (E58V 'plus one') increases IE E related transposition by 40,000 fold while removal of the mutation from Tnp sC7 (E58V 'minus one') drops the total activity by more than 1,000 fold. The mutation has comparatively little effect on OE related activity.

The mutation E344K exhibits a similar, though much weaker, sequence specific effect on activity. When removed from Tnp sC7 (E344K 'minus one'), IEE related activity decreases by 5 fold while OE related activity is stimulated about 5 fold. This result is mirrored in the 'plus ones' data as E344K in the wild type background stimulates IEM related activity 4 fold and decreases OE related activity about 5 fold.

Non-sequence-specific mutations. The mutation L372Q strongly stimulates Tnp sC7 activity with When removed from sC7 both IE m and OE related activity are reduced to the same degree. When added to wild-type transposase, its 'plus one' phenotype stimulates activity with both substrates.

Other mutations. The mutation R8C was the most interesting of the remaining four mutations. When the mutation is added to wild-type transposase, OE related WO 01/09363 PCT/US00/21052 transposition was reduced nearly 10 fold. When the mutation was removed from sC7 OE related activity increased approximately 2 fold. In a methylating host, its removal from sC7 had little effect on IE m related activity while by itself it decreased IE m related activity to below detectable levels. None of the remaining three (A157T, T171S, D217A) mutations has much effect on either IE M or OE related activity when removed from sC7. To determine whether any combination of these mutations would lead to an increase in overall IE m related activity without sacrificing its specificity for IE M over OE, the applicants engineered pairwise reversions of sC7 at these positions as well as a triple-reversion mutant. The construct with all three of these mutations reverted had the second highest IEM related activity and the best ability to discriminate between IE m and OE (Table This four-mutant construct, Tnp (R8C, E58V, E344K, L372Q), was renamed Tnp sC7 Table 3. In vivo frequency of Tnp sC7 with indicated mutations reverted to wild type.

Numbers in parenthesis indicate positions changed to wild-type.

IE OE IEm/OE freq. norm. freq. norm.

Tnp sC7 2.6X10 3 1.0 3.3X10 6 1.0 794 Tnp sC7(157,171) 6.5X10- 3 2.5 7.0X10 s 2.1 933 Tnp sC7(157,217) 8.4X10- 3 3.3 2.25X10- S 6.8 373 TnpsC7(171,217) 5.8X10- 3 2.3 1.18X10 5 3.6 502 Tnp sC7(157,171,217)a 7.4X10 3 2.8 7.1X10 6 2.1 1042 a Re-named sC7v2.0.

Abbreviations: OE outside end IE inside end

IE

M dam methylated inside end Tnp sC7 is less than the sum of its individual mutations. The Tnp E58V (E58V 'plus one') mutant has an activity increase of 4X 10" over Tnp WT alone. The composite mutant with E58V removed (E58V 'minus one') has an increase of 1.8X102 over Tnp WT. Additivity would then predict that Tnp sC7 would have an activity increase of: (4X10 4 )(1.8X10) 7.2X10 6 WO 01/09363 PCT/USOO/21052 However the stimulation of the composite mutation is actually much lower (2X10 5 In other words the increase obtained by adding E58V to the other 6 mutations is 1.1 fold, and not the 4X10 4 fold stimulation seen by adding E58V into the wild-type background. This may be because that E58V and E344K are both stimulating the same step (primary DNA binding) and are less than additive when combined.

Tnp sC7v2.0 effectively transposes IE M defined transposons in vitro The ability of Tnp sC7v2.0 to promote transposition of IE m defined transposons in vitro was tested under the same conditions developed for movement of OE defined transposons by Tnp EK/LP (Goryshin, and Reznikoff, "Tn5 in vitro transposition," J. Biol. Chem. 273:7367-7374 (1998), incorporated by reference as if set forth herein in its entirety). Substrate plasmid pGT4, a high-copy number pUC19-based vector in which inverted IE' end sequences flank a kanamycin resistance gene, was purified as a supercoiled monomer (see Materials and Methods). This plasmid was constructed so that digestion with PvuII restriction endonuclease causes release of the transposon from the donor backbone DNA (see Fig. 5A). Tnp sC7v2.0 was produced and purified by cloning the nucleotide sequence in an expression vector, expressing the protein in a host cell and isolating the protein from an extract from the host cell, all using standard methods known to a skilled artisan.

Incubation with Tnp sC7v2.0 results in conversion of 66% of supercoiled plasmid into transposition products and intermediates after a three hour incubation. In Fig. 5B, lane 1 is unreacted substrate pGT4. The transposition activity promoted by Tnp sC7v2.0 on IE m transposons is shown in lane 2 Lane 3 is the result of pGT4 digestion with PvulI restriction endonuclease.

Though transposition reactions performed in this fashion can lead to many different DNA products, the reaction can be interpreted by analyzing certain diagnostic fragments as defined previously by Goryshin and Reznikoff (1998), supra. Fig. 5C is a reproduction of lane 2 of Fig. 5B. Band 1 is the excised transposon. It is an intermediate that has undergone double ended break from the plasmid but has not undergone strand transfer. Band 2 is the donor backbone DNA that is released upon double-ended excision of the transposon. These bands have the same molecular weight as the products of the PvuII digest shown in lane 3 of Fig. 5B. Band 3 represents substrate plasmid that has undergone cleavage at one transposon end. It migrates at the same position as linearized plasmid (data not shown). Bands 4 and 5 are two different types of strand transfer products. Band 4 is the result of a transposon inserting intermolecularly into an unreacted plasmid. This results in a relaxed circular DNA that is longer than the original substrate plasmid by the length of the inserted transposon. The bands denoted as 5 are WO 01/09363 PCT/US00/21052 the result of intramolecular inversion events. These transposition products are the size of the transposon but circularized. These circularized transposition products can contain differing numbers of nodes and hence migrate in different positions on the gel.

Structure/function analysis The hyperactive Tn5 transposase mutant Tnp sC7v2.0, which increases transposition ofIEM flanked transposons by 7.4X10' times, includes mutations at amino acids 8, 58, 344, and 372. Analysis of Tnp sC7 revealed that the hyperactivity conferred by both the E58V and E344K mutations depends upon the transposon termini sequence.

This phenotype occurring for E58V was not surprising, as previous random mutagenesis screens performed with OE flanked transposons resulted in the isolation of proteins with mutations at either amino acid 47 or amino acid 54 which had sequence specific activity (Zhou and Reznikoff, 1997; Zhou,M., Bhasin,A., and Reznikoff,W.S., "Molecular genetic analysis of transposase-end DNA sequence recognition: cooperativity of three adjacent base-pairs in specific interaction with a mutant Tn5 transposase," J. Mol. Biol.

276:913-925 (1997)). The sequence specific activity of a mutation at amino acid 344 that suggests that the residue also interacts with transposon end DNA, however, was indeed very surprising.

Recently a protein-DNA co-crystal representing Tnp EK/LP complexed with pre-cut (no donor backbone) OE DNA has been solved. In this complex amino acid 58 is shown to interact specifically with OE at position 10. This places the mutant residue in the vicinity of position 12, the nucleotide mutation that it was initially chosen to repress. Positions 10, 11, and 12 are all different between IE and OE and furthermore it is near one of two areas that contain major groove modification by dam methylase (position 11 of top strand and position 12 of bottom strand).

The structure further shows that amino acid 344 interacts with DNA at position 7 of OE. While position 7 is not one of the seven that distinguishes IE from OE, it is between both position 4 and the region of nucleotides 10, 11, and 12 that differentiate the two. It is therefore plausible that the activity difference of Tnp E344K with IE and OE can be attributed to context effects of these two regions. We therefore propose that both mutations E58V and E344K are interacting with end sequence DNA and alter transposase function at the level of primary sequence recognition.

The leucine to glutamine mutation (L372Q), which was present in all sequenced mutants (sA5, sB2, sC6, sC7, and sD5), was both familiar and surprising. It was familiar because a hyperactive mutation at this position was previously isolated. It was surprising because the previously isolated mutation causes a leucine to proline (L372P) substitution at this position (Weinreich et al., 1994). The L372P mutation results in two -14- WO 01/09363 PCT/US00/21052 consecutive proline residues in an a helix. In the co-crystal this destabilizes amino acids 372-390. It is proposed that the mutation changes the conformation of the catalytic domain in relation to the C-terminal dimerization domain. This alteration can improve activity by increasing the distance between the N and C termini. The close proximity of these termini in Tnp WT is thought to decrease the rate of transposition of Tnp WT (Reznikoff et al., 1999). The wild-type leucine residue, visible in an earlier partial Tnp structure (Davies,D.R., Braam,L.M., Reznikoff,W.S. and Rayment,I., "The three-dimensional structure of a Tn5 transposase-related protein determined to 2.9-A resolution," J Biol Chem. 274: 11904-11913 (1999)), is buried in a hydrophobic pocket.

It is likely that substitution with a glutamine destabilizes this hydrophobic packaging.

Given that two different hyperactive mutations have been isolated by PCR-base random mutagenesis techniques that only result in single nucleotide changes in the codon and can only make five different amino acid substitutions at this residue (methionine, valine, arginine, proline, or glutamine), it is likely that a more direct mutagenesis approach such as codon randomization could reveal other interesting mutants.

The mutation R8C, which reduces OE related transposition almost 10-fold in the wild-type background (R8C 'plus one') and increases it approximately 2-fold when removed from the sC7 background (R8C 'minus one') is less easy to interpret. In the co-crystallographic structure the arginine residue is not in an area of DNA contact.

However this structure only represents a still picture of the complex after cleavage has occurred and it is possible that this region contacts DNA in the initial synapse.

IE methylation The inside end of the Tn5 transposon contains two GATC signal sequences that add four methyl groups into the major groove of each end. In this study, we were able to isolate a single mutation, E58V, which not only overcomes this binding inhibition but also appears to preferentially function on transposons in which the methyl groups are present (presumably due to increased binding affinity). Furthermore, the co-crystal structure of Tnp EK/LP complexed with pre-cleaved DNA shows that glutamate 58 interacts directly with position 10 of OE in the major groove. This region is in the vicinity of the methyl group that is present on the adenine of the non-transferred strand of IE

M

The fact that a single amino acid change can result in this extreme change in phenotype leads us to propose that this methyl group alone is responsible for the inhibition of binding of transposase to IE

M

The inhibition of binding by Tnp WT to

IE

m is likely caused by an interaction between this methyl group and the negatively charged side chain of glutamate 58. Replacing this residue with a valine can not only remove this unfavorable interaction but also lead to an increase in binding affinity due to WO 01/09363 PCT/USOO/21052 hydrophobic packaging between the side chain of the valine residue and this methyl group.

General Materials and Methods Media and Reagents Papillation assays were performed using glucose minimal Miller media (Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. (1992)) supplemented with ampicillin, chloramphenicol, 5-bromo-4-chloro-3-indolyl-p- D-galactoside, and phenyl-p-D-galactoside (Trp--XG-PG plates) as described previously by Zhou, Reznikoff, supra. After transformation during site directed mutagenesis, the cells were outgrown in SOC media as indicated in the altered sites protocol (Promega). All other bacterial growth was performed in Luria Broth (Sambrook, Fritsch, E.F. Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, When necessary, antibiotics (Sigma) were added at the following concentrations: ampicillin 100 pg/ml; chloramphenicol 20pg/ml; nalidixic acid gentamycin 5tg/ml; tetracycline 15pg/ml. Taq DNA Polymerase, T4 polymerase, T4 ligase, dNTP's, and all components of the Altered Sites Mutagenesis kit were purchased from Promega. Restriction enzymes were purchased either from Promega or New England Biolabs. Oligonucleotides used in site directed mutagenesis, sPCR, and sequencing were purchased from Research Genetics. Radionucleotides used in sequencing were from Amersham.

Construction of plasmids Plasmid pGT4 was constructed as a high copy number plasmid containing a kanamycin resistance gene flanked by two inside ends. It is designed so that digestion with PvuII releases the transposon from its pUC vector backbone.

The fourteen pRZ9905 (sC7) derivatives and pRZ9905 (sC7 version 2.0) were constructed by swapping restriction fragments between pRZ9905 and pRZ9905 (sC7).

Bacterial Strains Cloning of plasmids and the directed evolution process were performed in JM 109 (Promega). The site-directed mutagenesis protocol utilized strain ES 1301 (Promega) and JM109. In the mating out assay, transposase plasmids were transformed into strain RZ212 [A(lac-proA,B), ar, str, recA56, sri, thi/pOX38-Gen], followed by conjugation into 14R525[F-nalr].

-16- WO 01/09363 PCT/US00/21052 Directed Evolution Process Directed evolution ofTn5 transposase was carried out by sPCR, basically as described previously by Stemmer (1994). Forty micro liters of a pRZ9905 plasmid mini prep (Wizard SV preps, Promega) were partially digested in a 50pl volume containing 100mM Tris-HCI (ph 5nM MgCl, and 90ng of DNase I. After a 7-minute incubation at room temperature, the reactions were stopped by adding EDTA to Following the addition of loading dye (Sambrook et. al, 1989) the digested DNA was electrophoresed in a 2% NuSieve gel (FMC BioProducts) next to pGEM DNA markers (Promega). A gel slice containing DNA fragments of 200-600bp in size as well as a second slice containing DNA fragments from 600-1000bp in size were excised from the gel. The DNA from these two slices was purified separately by phenol chloroform extraction (Sambrook et. al, 1989). After ethanol precipitation, the DNA pellets were dried and resuspended directly into 50 pl of an assembly reaction mix. The assembly mix contained 0.2mM dNTP's; 2.0mM MgCI; 50mM KCI; 10mM Tris-HCI (pH9.0 at 25C); and 0.1% Triton X-100. After addition of 0.5 units ofTaq DNA Polymerase, the DNA was reassembled by the following thermo cycling program: 94C for 30seconds; cycles of 94C for 20 seconds, 65C for 1 minute, and 72C for 2 minutes; and cooling to 4C. A standard PCR amplification reaction using 5pl of the assembly reaction product as a DNA template was performed for each sample (200-600bp and 600-1000bp) to amplify the transposase gene. This transposase-encoding fragment was digested to completion with AflII and BglII and ligated into purified AflII/BglII digested vector DNA from pRZ9905.

Ligation products were transformed into electrocompetent JM109 cells that contained plasmid pRZ9904 (IEl2A/IE12A). After outgrowth the cells were plated on Trp-XG-PG plates with chloramphenicol and ampicillin selection. The plates were incubated at 32C for 14 days. At this time pRZ9905 plasmid DNA from all colonies that exhibited at least one papillae were isolated and re-transformed into the papillation assay to confirm their papillation plus phenotype. A total of 5 pRZ9905 derivatives (out of 20,000 original colonies screened) were confirmed to be papillation plus. An equal amount of all five plasmids was then used as the substrate for a second round of mutagenesis and screening. This process was repeated for a total of four rounds of screening 20,000 colonies round) Quantitative Papillation Assay The IE12A in vivo transposition activity of Tnp WT, Tnp sA5, Tnp sB2, Tnp sC6, and Tnp sD5 were compared by a quantitative papillation assay. Competent cells of strain JM109 harboring plasmid pRZ9904 (IEI2A/IE12A) were transformed with the WO 01/09363 PCITUS00/21052 appropriate transposase-encoding version ofpRZ9905. After outgrowth, transformed cells were plated on Trp-XG-PG plates with chloramphenicol and ampicillin. The plates were grown at 32C until colonies began to appear (~18 hours). Individual colonies were then picked with sterile sticks and spotted onto a fresh plate in a 4X4 grid pattern to evenly space all colonies. One plate of 16 colonies was spotted for each protein. Plates were incubated at 32C and quantified for transposition by observing the appearance of papillae at 24-hour intervals. Data are expressed as the average number of papillae present per colony.

Mating out assays Mating out assays were performed as described previously (Yin et al., 1988; Goryshin et al., 1994). Bacterial cells with the transposon containing plasmids pFMA52-187 (with either two OEs or two IEs) and the F factor pox-Gen were transformed with the appropriate transposase encoding plasmid pRZ9905. The donor used for the library screening was the strain JCM101 (AlacZX74, raps, dam-3]. All other mating out was performed in E. coli strain RZ212 [A(lac-proA,B), ara, str, recA56, sri, thi]. The recipient strain used was 14R525[F-nalr]. A total of three assays were performed for each combination of transposase and end sequence. The values reported are the average of these three data points.

In vitro transposition assays Substrate plasmid pGT4 was isolated from DH5a cells using a qiafilter plasmid mega kit (Qiagen). Supercoiled monomer plasmid was isolated from a 1% agarose gel by use of the qiaquick gel purification kit (Qiagen). Reactions were performed at 37C under conditions determined by Reznikoffand Goryshin (1998). The concentration of pGT4 was 35.5nM. Tnp sC7v2.0 was added to a concentration of 280nM.

The foregoing is not intended to limit the scope of the invention. Rather the invention is understood to encompass all the variations and modifications that come within the scope of the appended claims.

EDITORIAL NOTE APPLICATION NUMBER 63967/00 The following Sequence Listing pages 1 to 7 are part of the description. The claims pages follow on pages 19 to WO 01/09363 WO 0109363PC/USOO/2 1052 SEQUENCE LISTING <1.10> Reznikoff, William S Naumann, Todd A <120> Transposase Enzyme and Method for Use <130> 960296.96471 <140> <141> <150> 60/146686 <151> 1999-08-02 <160> <170> Patentln Ver. 2.1 <210> <211> <212> <213> <220> <221> <222> 1 1431

DNA

Transposon C3DS (1428) <400> 1 atg ata act Met Ile Thr 1 tct gct ctt cat cgt gcg gcc gac tgg gct aaa tct gtg 48 Ser Ala Leu His Arg Ala Ala Asp Trp Ala Lys Ser Val tc tct tcg Phe Ser Ser aac gtc gcc Asn Val Ala gcg gcg Ala Ala ctg ggt gat Leu Gly Asp cct cgc cgt act gcc cgc ttg gtt 96 Pro Arg Arg Thr Ala Arg Leu Val 25 tat tct ggt aaa tca ata acc atc 144 Tyr Ser Gly Lys Ser Ile Thr Ile gcc caa ttg Ala Gin Leu gca aaa Ala Lys 40 tca tca gag Ser Ser Glu ggt agt gaa gcc atg cag gaa ggc Gly Ser Glu Ala Met Gln Glu Gly 55 gct tac cga ttt atc 192 Ala Tyr Arg Phe Ile WO 01/09363 WOO1/9363PCT/UJSOOI2I 052 cgc aat Arg Asn ccc aac gtt tct gcc gag gcg atc aga aag gct ggc gcc Pro Asn Val Ser Ala Giu Ala Ile Arg Lys Ala Gly Ala caa aca gtc aag ttg gct cag gag tt Gin Thr Val Lys Leu Ala Gin Glu Phe gaa ctg ctg gcc Glu Leu Leu Ala att gag Ile Giu gac acc acc Asp Thr Thr aag ctg ggc Lys Leu Gly 115 gtt ctc ttg Vai Leu Leu 130 ttg agt tat cgc Leu Ser Tyr Arg cag gtc gcc gaa Gin Val Ala Giu gag ctt ggc Giu Leu Giy 110 gtt cac tcc Val His Ser tct att cag gat Ser Ile Gin Asp tcc cgc gga tgg Ser Arg Gly Trp, ctc gag gcc Leu Glu Ala aca ttc cgc acc Thr Phe Arg Thr gga tta ctg cat Gly Leu Leu His gag tgg tgg atg Glu Trp Trp Met ccg gat gac cct Pro Asp Asp Pro gat gcg gat gaa Asp Ala Asp Glu gag agt ggc aaa tgg ctg gca gcg gcc Giu Ser Gly Lys Trp Leu Ala Ala Ala 165 act agc cgg tta Thr Ser Arg Leu cgc atg Arg Met 175 ggc agc atg Giy Ser Met att cat gct Ile His Ala 195 gtg cgc tee Vai Arg Ser 210 age aae gtg att Ser Asn Val Ilie gte tgt gac cge Val Cys Asp Arg gaa gec gat Glu Ala Asp 190 ege tte gtg Arg Phe Val tat ctg cag gac Tyr Leu Gin Asp ctg geg cat aae Leu Ala His Asn aag cac cca Lys His Pro aag gac gta gag Lys Asp Val Glu ggg ttg tat ctg Gly Leu Tyr Leu gac cat etg aag Asp His Leu Lys caa ceg gag Gin Pro Giu tig ggt Leu Gly 235 ggc tat cag Gly Tyr Gin ate age Ile Ser 240 WO 01/09363 WO 0109363PCr/USO0121052 att ceg eaa aag Ile Pro Gin Lys gtg gtg gat aaa Val Val Asp Lys egc Arg 250 ggt aaa egt aaa aat ega Giy Lys Arg Lys Asn Arg 255 eca gcc cgc Pro Ala Arg aaa cag ggg Lys Gin Gly 275 gcg age ttg age Ala Ser Leu Ser cge agt ggg ege Arg Ser Gly Arg ate aeg eta Ile Thr Leu 270 gag att aae Giu Ile Asn aat atc aeg etc Asn Ile Thr Leu gcg gtg etg gc Ala Val Leu Ala eeg ec Pro Pro 290 aag ggt gag ace Lys Gly Giu Thr ttg aaa tgg ttg Leu Lys Trp Leu etg ace age gaa Leu Thr Ser Glu ceg Pro 305 gte gag teg eta Val Glu Ser Leu caa gee ttg ege Gin Ala Leu Arg ate gac att tat Ile Asp Ile Tyr 912 960 1008 cat ege tgg egg His Arg Trp, Arg gag gag tte cat Giu Giu Phe His gca tgg aaa ace Ala Trp Lys Thr gga gea Gly Ala 335 gga gee gag Giy Ala Glu gte teg ate Val Ser Ilie 355 caa ege atg gag Gin Arg Met Giu ceg gat aat ctg Pro Asp Asn Leu gag egg atg Glu Arg Met 350 etc aga gaa Leu Arg Giu etc teg ttt gtt Leu Ser Phe Val gte agg etg tta Val Arg Leu Leu 1056 1104 1152 1200 age tte Ser Phe 370 geg gaa Ala Glu 385 aeg etg ceg Thr Leu Pro caa gca Gin Ala 375 etc agg geg caa Leu Arg Ala Gin tee gca gaa aeg Ser Ala Glu Thr 395 ggg Gly 380 etg eta aag gaa Leu Leu Lys Giu eac gta gaa age cag His Val Glu Ser Gin 390 gtg ctg ace ceg Val Leu Thr Pro gaa tgt eag eta Giu Cys Gin Leu ctg ggc tat ctg gac aag gga aaa ege aag ege aaa Leu Giy Tyr Leu Asp Lys Gly Lys Arg Lys Arg Lys 405 410 415 1248 WO 01/09363 gag aaa gca Glu Lys Ala PCT/USOO/21052 agc ttg cag tgg gct tac atg gcg ata Ser Leu Gin Trp Ala Tyr Met Ala Ile 425 gct aga ctg Ala Arg Leu 430 tgg ggc gcc Trp Gly Ala 1296 ggc ggt ttt Giy Gly Phe 435 atg gac agc Met Asp Ser aag cga Lys Arg 440 acc gga att gcc Thr Gly Ile Ala 1344 ctc tgg gaa ggt tgg gaa Leu rrp Giu Gly Trp Giu 450 ctg caa agt aaa Leu Gin Ser Lys gat ggc ttt ctt Asp Gly Phe Leu 1392 gc Ala 465 gcc aag gat ctg Ala Lys Asp Leu gcg cag ggg atc Ala Gin Giy Ile aag atc tga Lys Ile 475 1431 <210> 2 <211> 476 <212> PRT <213> Transposon <400> 2 Met Ile 1 Thr Ser Ala Leu His Arg Ala 5 Asp Trp Ala Lys Ser Val is Phe Ser Ser Asn Val Ala Ala Leu. Giy Asp Arg Arg Thr Ala Arg Leu Val Ile Thr Ile Ala Gin Leu Ala Tyr Ser Giy Lys Ser Ser Giu Gly Ser Giu Met Gin Giu Gly Tyr Arg Phe Ile Asn Pro Asn Vai Ala Glu Ala Ile Lys Ala Gly Ala Gin Thr Val Lys Leu Ala Gin Giu Phe Giu Leu Leu Ala Ile Giu Giu Leu Gly 110 Asp Thr Thr Ser Leu 100 Ser Tyr Arg Gin Val Ala Giu WO 01/09363 Lys Leu Gly 115 PCT/IJSOOt2 1052 His Ser Ser Ile Gin Asp Lys Ser Arg Gly Trp Trp Val 120 125 Val Leu 130 Gin Giu 145 Giu Ser Gly Ser Ile His Val Arg 210 Tyr Asp 225 Ile Pro Leul Trp Gly Met Ala 195 Ser His Gin Arg Giy 275 Lys Giu Trp, .eu Giu Ala rrp Lys M4et 180 Tyr Lys Leu Lys Lys 260 Asn Gly Ser Arg Met Arg 150 Trp Leu 165 Scr Asfl Leu Gin His Pro Lys Asn 230 Gly Val 245 Ala Ser Ile Thr Giu Thr Leu Ala 310 Ile Giu 325 Thr 135 Pro Ala Thr Phe Arg Asp Asp Pro Ala Ala Ala 170 Thr Val 140 Ala Asp 155 Thr Ser Val Ile Asp Lys 200 Arg Lys 215 Gin Pro Val Asp Leu Ser Leu Asn 280 Pro Leu 295 Gin Ala Giu Phe Ala Val 185 Leu Ala Asp Val Giu Leu Lys Arg 250 Leu Arg 265 Ala Val Lys Trp Leu Arg His Lys 330 Cys Asp Arg His Asn Glu 205 Giu Ser Gly 220 Gly Gly Tyr 235 Gly Lys Arg Ser Gly Arg Leu Ala Giu 285 Leu Leu Leu 300 Val Ile Asp 315 Ala Trp Lys Leti Asp Leu GlU 190 Arg Leu Gin Lys Ile 270 Glu Thr Ile Thr Leu Giu Arg 175 Ala Phe Tyr Ile Asn 255 Thr Pro Lye Pro Pro 305 His Ala Gin Pro 290 Val Arg Asn Ser Glu Tyr Thr 320 Gly Ala 335 Gly Ala Glu Gin Arg Met Giu Pro Asp Asn Leu Giu Arg Met 350 WOO01109363 Val Ser Ile 355 PCT/LJSOO/2 1052 Leu Ser Phe Val Ala 360 Val Arg Leu Leu Leu Arg Glu Ser Phe 370 Thr Leu Pro Gin Ala 375 Leu Arg Ala Gin Leu Leu Lys Glu Ala 385 Glu His Vai Giu Gin Ser Ala Giu Val Leu Thr Pro Giu Cys Gin Leu Gly Tyr Leu Asp Gly Lys Arg Lys Arg Lys 415 Giu Lys Ala Gly Giy Phe 435 Ser LeU Gin Trp Ala Tyr Met Ala Ile 425 Ala Arg Leu 430 Trp Gly Ala Met Asp Ser Lys Thr Gly Ile Ala Leu Trp 450 Giu Giy Trp Glu Leu Gin Ser Lys Asp Gly Phe Leu Ala 46S Ala Lys Asp Leu Ala Gin Gly Ile Lys Ile 475 <210> 3 <211> 19 <212> DNA <213> Transposon <400> 3 ctgactctta tacacaagt <210> 4 <211> 19 <212> DNA <213> Transposon TnS <400> 4 ctgtctcttg atcagatct WO 01/09363 PCTIUSOOflI 052 <210> <211> 19 <212> DNA <213> Transposon 5<400> ctgtctcttg aacagatct 19 -7-

Claims (17)

1. An isolated mutant Tn5 transposase protein modified relative to wild-type transposase protein, the mutant transposase differing from the wild-type protein at a position selected from the group consisting of amino acid 58 and amino acid 372, wherein the mutant Tn5 transposase protein has a preference for Tn5 inside ends over Tn5 outside ends.

2. The mutant Tn5 transposase as claimed in claim 1 comprising a valine at amino acid position 58.

3. The mutant Tn5 transposase as claimed in claim 1 comprising a mutation at 0o amino acid position 372.

4. The mutant Tn5 transposase as claimed in claim 1 comprising a glutamine at amino acid position 372. The mutant Tn5 transposase as claimed in claim 1, wherein the mutant transposase differs from the wild-type protein at amino acids 58 and 372.

6. The mutant Tn5 transposase as claimed in 1 comprising a valine at amino acid position 58 and a glutamine at amino acid position 372.

7. The mutant Tn5 transposase as claimed in claim 1 further differing from wild- type Tn5 transposase at a position selected from amino acid 8 and amino acid 344.

8. The mutant Tn5 transposase as claimed in claim 7 wherein the amino acid at position 8 is cysteine.

9. The mutant Tn5 transposase as claimed in claim 7 wherein the amino acid at position 344 is lysine. o• The mutant Tn5 transposase as claimed in claim 7 wherein the mutant Tn5 transposase differs from wild-type Tn5 transposase at amino acid position 8 and amino acid position 344.

11. The mutant Tn5 transposase as claimed in claim 1 comprising a cysteine at amino acid position 8 and a lysine at amino acid position 344.

12. The mutant Tn5 transposase as claimed in claim 1 comprising a cysteine at amino acid position 8, a valine at amino acid position 58, a lysine at amino acid position 344, and a glutamine at amino acid position 372.

13. A polynucleotide that encodes a transposase as claimed in claim 1.

14. A polynucleotide that encodes a transposase as claimed in claim 12. A system for transposing a transposable DNA sequence in vitro, the system comprising: [I:\DAYLIB\LIBFF]06494.doc NSS the mutant Tn5 transposase modified relative to a wild-type Tn5 transposase, as claimed in claim 1; a donor DNA molecule comprising the transposable DNA sequence, the sequence being flanked at its and 3' ends by a wild-type IE sequence; and a target DNA molecule into which the transposable element can transpose.

16. A system as claimed in claim 15 wherein the IE sequence is methylated.

17. A method for in vitro transposition, the method comprising the steps of: combining a donor DNA molecule that comprises a transposable DNA sequence of interest, the DNA sequence of interest being flanked at its and ends by a wild-type Tn5 inside end sequence, with a target DNA molecule and a mutant Tn5 transposase as claimed in claim 1 in a suitable reaction buffer for a period of time sufficient for the enzyme to catalyse in vitro transposition.

18. An isolated mutant Tn5 transposase protein modified relative to wild-type transposase protein, the mutant transposase differing from the wild-type protein at a position selected from the group consisting of amino acid 58 and amino acid 372, substantially as hereinbefore described with reference to any one of the examples.

19. A polynucleotide that encodes a transposase as claimed in claim 18. A system for transposing a transposable DNA sequence in vitro, substantially as hereinbefore described with reference to any one of the examples.

21. A method for in vitro transposition, substantially as hereinbefore described with reference to any one of the examples. Dated 31 May, 2004 Wisconsin Alumni Research Foundation Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON *a (l:\DAYLIB\LIBFF06494 doc NSS